Clinical trial
A Study of an Investigational Medication for the Treatment of Secondary…
NCT00042653 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00042653 |
|---|---|
| Title | A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis |
| Official title | A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Secondary Hyperparathyroidism, End Stage Renal Disease |
| Intervention type | Drug |
| Interventions | Placebo, AMG 073 |
| Enrollment | 380 |
| Start date | May 1, 2002 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Aug 6, 2002 |
| Last update posted | May 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: